Skip to main content

Clinical Trials Using Trastuzumab Emtansine

Review the clinical trials studying trastuzumab emtansine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Status: Active
Location: 145 locations
Trastuzumab Emtansine Followed by Trastuzumab versus Paclitaxel in Combination with Trastuzumab for the Treatment of HER2-Positive Stage I Breast Cancer, ATEMPT 2.0 Trial
Status: Active
Location: 33 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 35 locations
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer that had Already Spread at Diagnosis
Status: Active
Location: 21 locations
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage I-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery
Status: Active
Location: 15 locations
Trastuzumab Emtansine and Chemoradiation for the Treatment of HER2-Positive, Resectable Stage II-IVB Salivary Gland Cancer
Status: Active
Location: 13 locations
A New Molecular Biomarker Test for Adapting Neoadjuvant Treatment in Patients with HER2-Positive Early-Stage Breast Cancer, EUREKA Trial
Status: Active
Location: 9 locations
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Status: Active
Location: 9 locations
A Study Using ctDNA to Guide Treatment for People with HER2-positive Breast Cancer, HERizon-Breast Trial
Status: Active
Location: 7 locations
Sequential Combination Therapy for the Treatment of Patients with De Novo Metastatic Breast Cancer, The SAPPHO Study
Status: Active
Location: 5 locations
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Status: Active
Location: 3 locations
Tucatinib and T-DM1 for the Treatment of Patients with HER2-Positive Metastatic Solid Tumors and Brain Metastases, TUCATEMEB Study
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Capecitabine or Trastuzumab Emtansine with Radiation Therapy for the Treatment of High-Risk Stage I-IIIB Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: See ClinicalTrials.gov